Table 1 Clinical characteristics of patients with gastric cancer receiving adjuvant TS-1 and 5-fluorouracil chemotherapy
| Â | TS-1 adjuvant group, n (%) | 5-fluorouracil adjuvant group, n (%) | p value |
|---|---|---|---|
Total | 40 (100) | 193 (100) | Â |
Male gender | 24 (60) | 123 (63.7) | 0.39 |
Median age (range) | 61.0 (27 to 88) | 61.1 (27 to 90) | 0.63 |
ECOG performance status scale | Â | Â | Â |
 0 | 32 (80) | 133 (68.9) | 0.24 |
 1 | 7 (17.5) | 47 (24.4) |  |
 2 | 1 (2.5) | 13 (6.7) |  |
Histological type | Â | Â | Â |
 Intestinal | 15 (37.5) | 61 (31.6) | 0.29 |
 Diffuse | 25 (62.5) | 132 (68.4) |  |
Gastrectomy method | Â | Â | Â |
 Subtotal | 25 (62.5) | 124 (64.2) | 0.48 |
 Total | 15 (37.5) | 69 (35.8) |  |
TNM stage (AJCC, 6 th ) | Â | Â | Â |
 Ib | 5 (12.5) | 48 (24.9) | 0.12 |
 II | 17 (42.5) | 46 (23.8) |  |
 IIIa | 8 (20) | 51 (26.4) |  |
 IIIb | 2 (5) | 13 (6.7) |  |
 IV | 8 (20) | 35 (18.1) |  |
Tumor stage (AJCC, 6 th ) | Â | Â | 0.14 |
 T1 | 6 (15) | 45 (23.3) |  |
 T2 | 22 (55) | 68 (35.2) |  |
 T3 | 9 (22.5) | 59 (30.6) |  |
 T4 | 3 (7.5) | 21 (10.9) |  |
Nodal stage (AJCC, 6 th ) | Â | Â | Â |
 N0 | 2 (5) | 28 (14.5) | 0.28 |
 N1 | 23 (57.5) | 97 (50.3) |  |
 N2 | 9 (22.5) | 50 (25.9) |  |
 N3 | 6 (15) | 18 (9.3) |  |